INTRODUCTION 36 37
Enterococci are commensal organisms in the gastrointestinal tracts of many 38 species from insects to humans (1), but also the third leading cause of hospital 39 infections (2, 3). They display intrinsic and acquired resistance to almost all 40 antibiotics in clinical use, and no single agent is able to kill more than 3 log 10 CFU/g 41 in vivo (4). Animal models of infection are invaluable tools for anti-infective 42 pharmacology and numerous in vivo enterococcal models have been used to test 43 old and new drugs, however, their validation for assessing the efficacy of 44 antimicrobial agents is frequently not reported (5). The enterococcal endocarditis 45 rabbit model is perhaps the most used, but it is also more expensive, cumbersome, 46 and centered on a tissue with complex pharmacokinetics (i.e., cardiac valves), 47 limiting its relevance for other systemic infections (6). Additionally, the usual lack of 48 a full dose-response curve hinders the determination of PK/PD indices necessary 49 to translate the results to humans (5, 7). Moreover, the bacterial growth in all 50 enterococcal models is either not quantified (e.g. peritonitis model) (8), poor (~1 51 log 10 CFU/g) or even negative (e.g. thigh infection) (9, 10) , and the variability is 52 high (e.g. rabbit endocarditis models) (11), particularly with vancomycin-resistant 53 strains (VRE) (12). Negligible growth and high dispersion may lead to inaccurate 54 estimation of antibiotic PD, as has been the case with daptomycin (13). 55
56
We optimized in vitro culture conditions of enterococci using anaerobic incubation 57 and mucin supplementation, aiming to enhance in vivo growth of vancomycin-58 susceptible (VSE) and VRE strains and to determine its impact on the PD of three 59 antibiotics: vancomycin (VAN), ampicillin-sulbactam (SAM) and piperacillin-60 tazobactam (TZP) . 61 62 Different aspects of this work were presented at the third ASM International 63
Conference on Enterococci and at the 51 st and 53 rd . 64 required to reach ~8 log 10 CFU/mL in the log phase (data not shown). For all 89 strains, 3 to 5 colonies from phase 0 were suspended in 10 mL of broth, serially 90 diluted 4 times (1:10), and incubated overnight at 37°C, keeping the same 91 atmosphere from the previous step (phase 1). The most diluted tube with complete 92 turbidity was selected, diluted further 1:100 in fresh broth, and incubated using the 93 same atmosphere from phase 1 until it reached the OD 580 corresponding to ~8.0 94 log 10 CFU/mL (phase 2). The broths used in phases 1 and 2 were BHI (Becton-95
Dickinson, USA) for the aerobic groups and thioglycollate USP (a reducing medium 96 from Oxoid, United Kingdom) for the anaerobic groups. Bacteria from phase 2 were 97 diluted in the corresponding media to the desired final inoculum size, which varied 98 from 5 to 8 log 10 CFU/mL according to the experiment. In some in vivo experiments 99 (described below), the inoculum from phase 2 was supplemented with mucin just 100 before inoculation by mixing autoclaved 10% w/v stomach porcine mucin Aldrich, USA) with the culture broth (BHI or thioglycollate) in equal volumes, 102 obtaining a final mucin concentration of 5% (18) . 103
104

Animal model. The University of Antioquia Animal Experimentation Ethics 105
Committee reviewed and approved the experimental protocol. Six-week old Murine-106
Pathogen-Free female mice of the strain Udea:ICR(CD-2) weighing 23 to 27 g were 107 rendered neutropenic (<100 neutrophils/mm 3 ) by the intraperitoneal injection of two 108 doses of cyclophosphamide (Endoxan®, Baxter, Germany) 4 days (150 mg/kg) and 109 1 day (100 mg/kg) before infection (19). Sixteen hours later, isoflurane (Isorane®, 110 Abbott, Argentina) anesthetized animals were infected intramuscularly in each thigh 111 with 0.1 mL of the selected inoculum. During the standardization of the model, mice 112 were separated into four experimental groups (n≥10 animals/group), according to 113 the inoculum conditions used: aerobiosis (non-supplemented broth); 114 aerobiosis+mucin (incubated under aerobic atmosphere, broth supplemented with 115 5% porcine mucin); anaerobiosis (non-supplemented broth); anaerobiosis+mucin 116 (incubated under anaerobic atmosphere, broth supplemented with 5% mucin). A 117 minimum of two animals per group were picked from their cages at random and 118 sacrificed immediately after inoculation (0 h), at five or more of the following time-119 points: 1, 2, 4, 6, 8, 10, 12, 14, 18 hours, and allocating 2 mice per dose and encompassing at least 6 doses from no effect to 157 maximal effect. The doses ranged from 2.34 to 600, 18.75 to 2400, and 18.75 to 158 4800 mg/kg/day for VAN, SAM and TZP, respectively, in all cases divided every 3 h 159 (q3h). At the end of treatment, the thighs of each mice were dissected aseptically, 160 37ºC. The limit of detection was 100 CFU/thigh, which in this model is equivalent to 162 2 log 10 CFU/g. In addition, we included 2 untreated control mice per experiment that 163 received 0.2 mL subcutaneous injections of sterile saline q3h and were sacrificed 164 and processed as the experimental groups at 3 time-points: just after inoculation (-165 2h), at the onset (0h), and at the end (24h) of therapy. 166 167 Statistical analysis. Bacterial counts were stored in an Excel database (Microsoft, 168 Seattle, WA) for subsequent analysis. In vivo growth (G) was established by an 169 empirical equation and as a parameter derived from a nonlinear regression (NLR). 170
In the former case, the net growth (ΔG 26-2 ) was defined simply by subtraction of the 171 mean number of bacteria observed 2 h after infection from those reached at 26 h 172 (19, 20) . In the latter, in vivo growth-time curves were fitted using a NLR analysis 173 described by a modified Gompertz's equation (see Table S1 in supplemental 174 material) (21). The magnitude of the parameters derived from this equation were 175 compared by curve fitting analysis (CFA; Prism 6.04) (22, 23) . A successful in vivo 176 model was defined as one that attained four criteria: (i) net growth ΔG 26-2 ≥1.5 log 177 CFU/g, (ii) significant parameters derived from Gompertz's equation fulfilling the 178 homoscedasticity and normality assumptions, (iii) a difference between the maximal 179 and minimal predicted bacterial count ≥2 log CFU/g (Auctus in Table S1 ), and (iv) 180 standard error of estimate (S y|x ) ≤0.5 logs. Dissemination data to blood and spleen 181 26 h post-infection were compared with ANOVA for normally distributed data (see 182 infection after 14 h. Due to its low growth, high error and high similarity to aerobiosis 213 (Table S1 ), the anaerobiosis condition was not tested anymore. 214
215
The comparison of immunocompetent vs. neutropenic mice using 216 anaerobiosis+mucin (inoculum of ~4 log 10 CFU per thigh) indicated that neutropenia 217 enhanced ΔG 26-2 by 1.26 log 10 CFU/g. The results with other strains are summarized 218 in supplemental Table S1 . 219 220 The animals injected with 5% sterile mucin had swelled thighs without signs of 221 systemic illness during the first day, after which the inflammation resolved 222 completely. At day 10 after mucin injection, all mice were alive and healthy. 223
Impact of mucin on systemic dissemination of E. faecium ATCC 19434. Taking 225
into account the similar in vivo growth reached in mice inoculated with E. faecium 226 19434 using anaerobiosis+mucin versus aerobiosis+mucin (Table S1 ), we 227 compared the dissemination to distant organs 26 h after infection. A higher bacterial 228 burden in spleen (P<0.001 by ANOVA) and blood (P=0.0002 by KW) was observed 229 using anaerobiosis+mucin (for details see Figure S1 ). Table 1 and the PD parameters of VAN, SAM, and TZP obtained 235 using different inoculum conditions are shown in Table 2 . In all cases, mucin 236 supplementation led to high in vivo growth (ΔG 26-2 ≥1.85 log 10 CFU/g) and yielded 237 significant PD parameters (Adj. R 2 ≥0.94). In contrast, the aerobiosis group 238 changed depending on the group tested and there was a significant difference 251 (P<0.0001 by global CFA) on PD parameters (Table 2) it is available to induce damage in vivo even after the atmosphere switches. 292
Regarding mucin, it is a heavily glycosylated cysteine-rich protein that covers the 293 epithelium of the gastrointestinal tract, and is a potential natural source of amino 294 acids and sugars for enterococci (36-39). 295
296
There has been at least one previous attempt to improve the enterococcal thigh 297 infection model. Eguchi et al. supplemented the inoculum with carrageenan, a 298 tissue irritant used in models of inflammatory pain, enhancing net growth (ΔG 26-2 = 299 1.41 logs) in neutropenic mice but also increasing the standard deviation (SD = 1.04 300 log 10 CFU/g at 26 h) (40). We think that our model with anaerobiosis+mucin is better 301 because it enhanced the net growth of susceptible and resistant strains (ΔG 26-2 302 >1.6, Table S1) without increasing the dispersion of the data (coefficient of variation 303 <40% vs. 74% from Eguchi et al.) . This is a major point because the power of any dotted lines indicate that the regression did not fit or failed the presumptions of normality or homoscedasticity (see Table  520 S1). 
